Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586173 | 0.73 | NOTUM (0.40) | NOTUM | |
| SCHEMBL1521939 | 0.71 | MAPT (0.31) | MAPT | |
| SCHEMBL1195972 | 0.70 | NOTUM (0.46) | NOTUMALDH1A1NPSR1MAPTF2 | |
| SCHEMBL12615992 | 0.70 | ALDH1A1 (0.68) | NOTUMALDH1A1NPSR1MAPTF2 | |
| SCHEMBL586172 | 0.69 | CYP2A6 (0.42) | ALDH1A1LMNAHTTKMT2AKDM4E | |
| SCHEMBL28511732 | 0.69 | ALDH1A1 (0.47) | NOTUMALDH1A1NPSR1MAPTF2 | |
| SCHEMBL17714518 | 0.68 | NOTUM (0.41) | NOTUMALDH1A1NPSR1MAPTF2 | |
| SCHEMBL28994295 | 0.67 | NOTUM (0.95) | NOTUMALDH1A1NPSR1MAPTF2 | |
| SCHEMBL3962509 | 0.67 | NOTUM (0.95) | NOTUMALDH1A1NPSR1MAPTF2 | |
| Hydrochloric Acid SCHEMBL2897369 | 0.67 | NOTUM (0.95) | NOTUMALDH1A1NPSR1MAPTF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103958495-A | Novel compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA | 2014-07-30 | — | — | CN | claimed |
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | claimed |
| EP-1928461-B1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | claimed |
| EP-2387564-A1 | BENZO ÝC¨PHENANTHRIDINES AS ANTIMICROBIAL AGENTS | Rutgers, The State University of New Jersey (US) | 2011-11-23 | — | — | EP | claimed |
| US-8037884-B2 | Modular system for patient positioning during medical procedures | ALLEN MEDICAL SYSTEMS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | claimed |
| WO-2010083436-A1 | BENZO [C] PHENANTHRIDINES AS ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-07-22 | — | — | WO | claimed |
| EP-2016064-B1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-03 | — | — | EP | claimed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | claimed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | claimed |
| US-20070260057-A1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | claimed |
| JP-2007505908-A | — | — | 2007-03-15 | — | — | JP | claimed |
| JP-2007504160-A | — | — | 2007-03-01 | — | — | JP | claimed |
| WO-2007019083-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | WO | claimed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | claimed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | claimed |
| EP-1663204-A2 | C-KIT MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | claimed |
| WO-2005020921-A2 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | NOTUM 3736/4885ALDH1A1 2953/4885NPSR1 41/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | NOTUM 3736/4885ALDH1A1 2953/4885NPSR1 41/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | NOTUM 3736/4885ALDH1A1 2953/4885NPSR1 41/4885 |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | NOTUM 4551/4885ALDH1A1 3160/4885NPSR1 52/4885 |
| US-20070260057-A1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | HTR3C, HTR3A, HTR3B | NOTUM 2205/4885ALDH1A1 2268/4885NPSR1 35/4885 |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | NOTUM 4551/4885ALDH1A1 3160/4885NPSR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.